Every 10-Q that Corvus Pharmaceu (CRVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVS filings page.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company advancing soquelitinib, ciforadenant and mupadolimab. For the quarter ended June 30, 2026, it reported a net loss of $18.0 million, and a $31.7 million net loss for the first half of 2026, reflecting higher research and development expenses of $27.1 million and general and administrative expenses of $7.0 million as clinical programs expanded.
Liquidity strengthened significantly: as of June 30, 2026, Corvus held $215.2 million in cash, cash equivalents and marketable securities, aided by a January 2026 follow-on public offering that raised net proceeds of $189.4 million. An amended at-the-market equity program provides up to $200.0 million of additional potential capacity, with no sales yet under this facility. Management believes current resources will fund planned operations for at least 12 months but anticipates the need for further capital to bring programs through commercialization.
The company continues to invest in its 48–49% equity stake in Angel Pharmaceuticals, contributing $5.0 million in a June 2026 financing and recording a $1.3 million share of Angel’s losses for the first half of 2026. Clinical highlights include an ongoing potentially registrational Phase 3 trial of soquelitinib in relapsed peripheral T cell lymphoma and a Phase 2 trial in atopic dermatitis following encouraging Phase 1 efficacy and safety data.
Corvus Pharmaceuticals reported a net loss of $13.7 million for the three months ended March 31, 2026, or $0.15 per basic and diluted share, compared with net income of $15.2 million a year earlier driven by a $25.1 million noncash gain from warrant revaluation. Operating expenses rose to $14.9 million as the company advanced its ITK inhibitor soquelitinib into a Phase 3 trial in relapsed peripheral T cell lymphoma and a Phase 2 trial in atopic dermatitis, and continued development of ciforadenant and mupadolimab. A January 2026 follow-on public offering of 9.1 million shares generated net proceeds of $189.4 million, lifting cash, cash equivalents and marketable securities to $236.7 million and extending the estimated cash runway into the second quarter of 2028.
Corvus Pharmaceuticals (CRVS) filed its Q3 2025 10‑Q, highlighting a clinical‑stage pipeline and continued operating losses. Cash, cash equivalents and marketable securities were $65.7 million as of September 30, 2025. Q3 operating expenses were $10.6 million, driven by R&D $8.5 million and G&A $2.1 million.
The company reported a Q3 net loss of $10.2 million. For the nine months, net loss was $3.0 million, reflecting a $27.1 million non‑cash gain from the change in fair value of its warrant liability. All common warrants from the May 2024 financing were exercised, delivering $54.3 million in proceeds and reducing the warrant liability to zero from $28.9 million at year‑end 2024; current liabilities fell to $8.1 million from $35.4 million.
Operating cash outflow was $23.6 million for the nine months, while financing inflows were $36.4 million. The company disclosed substantial doubt about its ability to continue as a going concern and noted it may seek additional funding, including under its $100 million at‑the‑market program with no sales to date. Shares outstanding were 74,681,872 as of November 4, 2025.